| Objective:Bronchial asthma Asthma,bronchial asthma is a variety of inflammatory cells and its associated factors involved in chronic airway inflammation,is a common type of chronic respiratory disease,the main clinical manifestations of chest tightness,wheezing,cough,shortness of breath,etc.symptom.A high prevalence of global asthma patients about 300 million and showing an increasing trend,about 30 million in China,and in recent years has gradually increased trend.In this study,we investigated the value of leukotriene receptor antagonist(Shun'ering)in the treatment of bronchial asthma in order to provide a reference for the clinical treatment of patients with bronchial asthma in a top three hospitals.In order to facilitate the clinical care workers to take appropriate treatment and care measures,so that the quality of life of bronchial asthma patients have improved.Methods:In this study,we selected 60 patients with asthma from 25 to 65 years old in the Department of Respiratory Medicine and the ward of a tertiary Hospital,from July 2016 to July 2017,as the research object.According to the principle of informed consent,the patients were randomly divided into two groups,each group of 30 cases.Record the general information of each subject,including basic information(age,gender,education,income level,allergy history,family history,etc.).FEV1,FEV1 / FVC(%)and PEF,asthma control score(ACT)and quality of life score were measured before treatment,and all patients were treated with budesonide fog Suspension and salbutamol aerosol,3 times a day,as the basis for the treatment of the study group on this basis to give montelukast sodium(Shun Erning)once a day as an intervention.People to regulate the medication,a monthly referral,The lung function index,ACT score and quality of life score were re-examined after 3 months.The measurement data were statistically described by X ± S,and the t-test was used to calculate the inferred statistics.The counting data were statistically described by frequency,rate or composition ratio.Chi-square test or correction of chi-square test to infer the statistics.Results:1.There was no significant difference between the two groups(P> 0.05).2.The average age,sex distribution,educational status,occupational distribution,income level and allergic rhinitis of the two groups were not statistically significant(P <0.05).The FEV1 of the study group was(2.62 ± 0.35)L,FEV1 / FVC was(81.33±9.90)ratio,and the PEF was(5.85 ± 1.30)L / s,which were significantly higher than those in the control group(P <0.05).3.There was no significant difference between the two groups in the correction of rank sum test(Z=-1.650,P=0.099).4.After 3 months of treatment,the ACT scores of the two groups were significantly improved,the study group score was 22.50 ± 2.58 points,higher than the control group 20.43 ± 4.37 points,the difference was statistically significant(t = 2.231,P = 0.031).5.After 3 months of treatment,the quality of life scores of the two groups were improved compared with those before treatment,and the activity score of the study group was(52.60 ± 7.72),the asthma symptom score(38.00 ± 3.15),the response to stimulate the original score(21.57 ± 3.82)and the total quality of life score(156.17 ± 17.33)were higher than those in the control group(P <0.05).There was no difference in the psychological status score between the two groups statistically significant(P> 0.05).Conclusions:1.Montelukast helps increase the one-second forced expiratory volume(FEV1)in patients with moderate-bronchial asthma in 25-65 years of age,FEV1 / FVC and expiratory flow at the first second forced expiratory volume(HRV)PEF)pulmonary function index.2.Montelukast helps bronchial asthma control asthma and improve the ACT score.3.Montelukast can improve the activity of bronchial asthma patients,relieve asthma symptoms,and reduce the response to stimulate the original,improve the quality of life of patients.4.There was no difference in clinical efficacy between the two groups of patients. |
PDF Full Text Request